Clinical trial • Phase III • Infectious Disease
Ibuzatrelvir for COVID-19
Phase III trial of Ibuzatrelvir for COVID-19. None/Not specified-controlled. 18 participants.
Overview
- Trial Therapeutic Area
- Infectious Disease
- Trial Disease
- COVID-19
- Trial Stage
- Phase III
- Drug Modality
- Small molecule
Key dates
- Initial CTIS Submission Date
- 26-02-2026
- First CTIS Authorization Date
- 01-04-2026
Trial design
None/Not specified-controlled Phase III trial in Belgium.
- Comparator
- None/Not specified
- Target Sample Size
- 18
Recruitment
- Digital Remote Recruitment
- True, recruitment contact includes email and telephone channels (PfizerVolRecruitment@pfizer.com, ClinicalTrials.gov_Inquiries@pfizer.com) enabling remote/digital enquiry and pre-screening.
- Planned Sample Size
- 18
- Recruitment Window Months
- 2
Methods
- Email contact (PfizerVolRecruitment@pfizer.com) and telephone (+3225567003) for volunteer recruitment targeted to healthy volunteers in Belgium; central sponsor contact via ClinicalTrials.gov_Inquiries@pfizer.com and +18007181021.
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 18
Belgium
- Earliest CTIS Part Ii Submission Date
- 20-03-2026
- Latest Decision Or Authorization Date
- 01-04-2026
- Processing Time Days
- 12
- Number Of Sites
- 1
- Number Of Participants
- 18
Sites
- Site Name
- Pfizer Clinical Research Unit
- Contact Person Name
- Constantino Kantaridis
- Contact Person Email
- PfizerVolRecruitment@pfizer.com
- Number Of Participants
- 18
Sponsor
Primary sponsor
- Full Name
- Pfizer Inc.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United States
Investigational products
- Investigational Product Name
- Ibuzatrelvir
- Active Substance
- Ibuzatrelvir
- Modality
- Small molecule
- Routes Of Administration
- oral (tablets)
- Route
- oral
- Authorisation Status
- Investigational
Related trials
Other published trials that may interest you.